Imperial College London

Professor Martin Wilkins

Faculty of MedicineDepartment of Medicine

Head of the Department of Medicine
 
 
 
//

Contact

 

+44 (0)20 3313 2049m.wilkins

 
 
//

Location

 

NIHR / Wellcome Trust Clinical Research FacilityICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@inbook{Rhodes:2013:10.1007/978-3-642-38664-0-4,
author = {Rhodes, CJ and Wharton, J and Wilkins, MR},
doi = {10.1007/978-3-642-38664-0-4},
pages = {77--103},
title = {Pulmonary hypertension: Biomarkers},
url = {http://dx.doi.org/10.1007/978-3-642-38664-0-4},
year = {2013}
}

RIS format (EndNote, RefMan)

TY  - CHAP
AB - Physicians look to biomarkers to inform the management of pulmonary hypertension (PH) at all stages, from assessing susceptibility through screening, diagnosis, and risk stratification to drug selection and monitoring. PH is a heterogeneous disorder and currently there are no accepted blood biomarkers specific to any manifestation of the condition. Brain natriuretic peptide and its N-terminal peptide have been most widely studied. Other candidate prognostic biomarkers in patients with pulmonary arterial hypertension (PAH) include growth and differentiation factor-15, red cell distribution width, uric acid, creatinine, inflammatory markers such as interleukin-6, angiopoietins, and microRNAs. Combining the measurement of biomarkers reflecting different components of the pathology with other modalities may enable better molecular characterisation of PH subtypes and permit improved targeting of therapeutic strategies and disease monitoring. © Springer-Verlag Berlin Heidelberg 2013.
AU - Rhodes,CJ
AU - Wharton,J
AU - Wilkins,MR
DO - 10.1007/978-3-642-38664-0-4
EP - 103
PY - 2013///
SN - 9783642386633
SP - 77
TI - Pulmonary hypertension: Biomarkers
UR - http://dx.doi.org/10.1007/978-3-642-38664-0-4
ER -